NurrOn Pharmaceuticals operates as an innovative pharmaceutical company.
NurrOn Pharmaceuticals has raised $1.7M in total funding. The most recent round was Grant. The last funding was announced in November 2024.
NurrOn Pharmaceuticals's investors include Michael J. Fox Foundation, Daewoong Pharmaceutical, HanAll Biopharma.
NurrOn Pharmaceuticals is headquartered in Woburn, United States.
NurrOn Pharmaceuticals operates as an innovative pharmaceutical company.
NurrOn Pharmaceuticals is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NurrOn Pharmaceuticals — Funding & Investors." VCBacked, November 25, 2024, https://www.vcbacked.co/company/nurron-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2024). NurrOn Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/nurron-pharmaceuticals
{{cite web |title=NurrOn Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/nurron-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated